Envestnet Asset Management
PRCT icon

Envestnet Asset Management’s Procept Biorobotics PRCT Stock Holding History

Envestnet Asset Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.18M Buy
140,664
+1,594
+1% +$39.9K ﹤0.01% 2801
2026
Q1 		$3.48M Buy
139,070
+51,007
+58% +$1.44M ﹤0.01% 2607
2025
Q4 		$2.77M Buy
88,063
+60,044
+214% +$1.99M ﹤0.01% 2593
2025
Q3 		$1,000K Sell
28,019
-2,492
-8% -$114K ﹤0.01% 3321
2025
Q2 		$1.76M Sell
30,511
-6,762
-18% -$382K ﹤0.01% 2916
2025
Q1 		$2.17M Sell
37,273
-4,929
-12% -$337K ﹤0.01% 2679
2024
Q4 		$3.4M Buy
42,202
+23,861
+130% +$2.04M ﹤0.01% 2349
2024
Q3 		$1.47M Buy
18,341
+7,689
+72% +$546K ﹤0.01% 2872
2024
Q2 		$651K Buy
+10,652
New +$634K ﹤0.01% 3309

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Envestnet Asset Management's PRCT Position: Q2 2026 in Review

Envestnet Asset Management increased its Procept Biorobotics (PRCT) stake by 1.1% in Q2 2026, buying an estimated $39.9K and bringing the position to 140,664 shares worth $3.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2801.

Envestnet Asset Management first reported a position in PRCT in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.48M in Q1 2026. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Envestnet Asset Management held 140,664 shares of Procept Biorobotics worth $3.18M as of Q2 2026.
  • Envestnet Asset Management bought 1,594 Procept Biorobotics shares in Q2 2026, an estimated $39.9K.
  • Procept Biorobotics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #2801 holding.
  • Envestnet Asset Management first reported a position in Procept Biorobotics in Q2 2024 and has held it in 9 quarters since.
  • Envestnet Asset Management's Procept Biorobotics position peaked at $3.48M in Q1 2026.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.